- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00474617
Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)
25 de março de 2019 atualizado por: Merck Sharp & Dohme LLC
A Multicenter, Parallel Group, Comparative, Phase IIIa Trial to Compare the Efficacy, Safety, and Pharmacokinetics of Org 25969 in Elderly Subjects With Adult Subjects
The purpose of the study is to compare the effectiveness, safety and pharmacokinetics of sugammadex in participants 65 and over with participants under 65.
There is no hypothesis defined for the study.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
162
Estágio
- Fase 3
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) Class 1 to 3
- 18 years of age or older
- Scheduled for elective surgical procedure under general anesthesia requiring neuromuscular block with the use of rocuronium
- Scheduled for surgery in supine position
- Given written informed consent
Exclusion Criteria:
- Participants in whom a difficult intubation is expected due to anatomical malformations
- Participants known or suspected to have neuromuscular disorders impairing neuromuscular blockade and/or significant renal dysfunction
- Participants known or suspected to have a (family) history of malignant hyperthermia
- Participants known or suspected to have an allergy to narcotics, muscle relaxants or other medications used during surgery
- Participants receiving medication known to interfere with neuromuscular blocking agents such as anticonvulsants, antibiotics and magnesium
- Female participants who are pregnant or breast-feeding
- Females participants of childbearing potential not using an acceptable method of birth control [condom or diaphragm with spermicide, vasectomized partner (> 6 months), intrauterine device (IUD), abstinence]
- Participants who had already participated in a Org 25969 trial including Protocol 19.4.305
- Participants who had participated in another clinical trial, not pre-approved by Organon, within 30 days of entering into Protocol 19.4.305
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Participants 18 to 64 years old
Participants to receive an intravenous (IV) single bolus dose of 0.6 mg.kg-1 rocuronium.
If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered.
After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of second twitch (T2) with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
|
Outros nomes:
intravenous (IV) single bolus dose of 0.6 mg.kg-1
|
Experimental: Participants 65 to 74 years old
Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium.
If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered.
After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
|
Outros nomes:
intravenous (IV) single bolus dose of 0.6 mg.kg-1
|
Experimental: Participants 75 years and older
Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium.
If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered.
After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
|
Outros nomes:
intravenous (IV) single bolus dose of 0.6 mg.kg-1
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Mean Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.9
Prazo: up to 10 minutes from start of sugammadex
|
Neuromuscular function was monitored by applying repetitive train-of-four (TOF) electrical stimulations with the TOF-Watch® SX to the ulnar nerve of one forearm every 15 seconds & assessing twitch response at the adductor pollicis muscle.
T1 and T4 are the magnitudes (heights) of the first and fourth twitches respectively after TOF nerve stimulation, where stimulation was continued until the T4/T1 ratio reached 0.9.
A higher T4/T1 ratio indicates a lower degree of neuromuscular blockade, with a value of 1.0 representing full recovery.
|
up to 10 minutes from start of sugammadex
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Mean Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.7
Prazo: up to 10 minutes from start of sugammadex
|
Neuromuscular function was monitored by applying repetitive train-of-four (TOF) electrical stimulations with the TOF-Watch® SX to the ulnar nerve of one forearm every 15 seconds & assessing twitch response at the adductor pollicis muscle.
T1 and T4 are the magnitudes (heights) of the first and fourth twitches respectively after TOF nerve stimulation, where stimulation was continued until the T4/T1 ratio reached 0.7.
A higher T4/T1 ratio indicates a lower degree of neuromuscular blockade, with a value of 1.0 representing full recovery.
|
up to 10 minutes from start of sugammadex
|
Mean Time From Start of Administration of to Recovery of the T4/T1 Ratio to 0.8
Prazo: up to 10 minutes from start of sugammadex
|
Neuromuscular function was monitored by applying repetitive train-of-four (TOF) electrical stimulations with the TOF-Watch® SX to the ulnar nerve of one forearm every 15 seconds & assessing twitch response at the adductor pollicis muscle.
T1 and T4 are the magnitudes (heights) of the first and fourth twitches respectively after TOF nerve stimulation, where stimulation was continued until the T4/T1 ratio reached 0.8.
A higher T4/T1 ratio indicates a lower degree of neuromuscular blockade, with a value of 1.0 representing full recovery.
|
up to 10 minutes from start of sugammadex
|
Participants Level of Consciousness Prior to Transfer to the Recovery Room After Extubation
Prazo: Prior to Transfer to the Recovery Room After Extubation (up to 24 hours)
|
Participants level of consciousness was assessed post-extubation and prior to transfer to recovery room.
The levels were reported as: awake and oriented; arousable with minimal stimulation; responsive only to tactile stimulation.
The number of participants in each of the 3 categories was summarized.
|
Prior to Transfer to the Recovery Room After Extubation (up to 24 hours)
|
Participants Level of Consciousness Prior to Discharge From Recovery Room
Prazo: Prior to Discharge from Recovery Room (up to 24 hours)
|
Participants level of consciousness was assessed prior to discharge from the recovery room.
The levels were reported as: awake and oriented; arousable with minimal stimulation; responsive only to tactile stimulation.
The number of participants in each of the 3 categories was summarized.
|
Prior to Discharge from Recovery Room (up to 24 hours)
|
Number of Participants With General Muscle Weakness Prior to Transfer to the Recovery Room After Extubation
Prazo: Prior to Transfer to the Recovery Room After Extubation (up to 24 hours)
|
The number of participants experiencing general muscle weakness was assessed by the investigator as a measure of recovery from neuromuscular blockade post-extubation and prior to transfer to recovery room.
A standardized examination form was used to determine the presence or absence of muscle weakness in various muscle groups and the overall assessments were reported as "yes" or "no" to general muscle weakness.
Participants who were not cooperative with the examination were not included in the assessment.
|
Prior to Transfer to the Recovery Room After Extubation (up to 24 hours)
|
Number of Participants With General Muscle Weakness Prior to Discharge From Recovery Room
Prazo: Prior to Discharge from Recovery Room (up to 24 hours)
|
The number of participants experiencing general muscle weakness was assessed by the investigator as a measure of recovery from neuromuscular blockade prior to discharge from the recovery room.
A standardized examination form was used to determine the presence or absence of muscle weakness in various muscle groups and the overall assessments were reported as "yes" or "no" to general muscle weakness.
Participants who were not cooperative with the examination were not included in the assessment.
|
Prior to Discharge from Recovery Room (up to 24 hours)
|
Number of Participants Who Can Perform a 5 Second Head Lift Prior to Transfer to the Recovery Room After Extubation
Prazo: Prior to Transfer to the Recovery Room After Extubation (up to 24 hours)
|
Participants were asked to lift their head off the table while in a supine position post-extubation and prior to transfer to recovery room.
The number of participants who could perform the 5 second head lift was summarized.
Participants who were not cooperative with the examination were not included in the assessment.
|
Prior to Transfer to the Recovery Room After Extubation (up to 24 hours)
|
Number of Participants Who Can Perform a 5 Second Head Lift Prior to Discharge From Recovery Room
Prazo: Prior to Discharge from Recovery Room (up to 24 hours)
|
Participants were asked to lift their head off the table while in a supine position just prior to discharge from the recovery room.
The number of participants who could perform the 5 second head lift was summarized.
Participants who were not cooperative with the examination were not included in the assessment.
|
Prior to Discharge from Recovery Room (up to 24 hours)
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
29 de dezembro de 2005
Conclusão Primária (Real)
20 de outubro de 2006
Conclusão do estudo (Real)
20 de outubro de 2006
Datas de inscrição no estudo
Enviado pela primeira vez
15 de maio de 2007
Enviado pela primeira vez que atendeu aos critérios de CQ
15 de maio de 2007
Primeira postagem (Estimativa)
17 de maio de 2007
Atualizações de registro de estudo
Última Atualização Postada (Real)
2 de abril de 2019
Última atualização enviada que atendeu aos critérios de controle de qualidade
25 de março de 2019
Última verificação
1 de março de 2019
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- P05950 (Outro identificador: Schering-Plough Study Number)
- 19.4.305 (Outro identificador: Organon Study Number)
- MK-8616-029 (Outro identificador: Merck Protocol Number)
Plano para dados de participantes individuais (IPD)
Dados/documentos do estudo
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Sugamadex
-
Rigshospitalet, DenmarkTrygFonden, DenmarkConcluídoIntubação de Sequência RápidaDinamarca
-
The Fourth Affiliated Hospital of Zhejiang University...Ainda não está recrutando